CoChat

Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial

Jayaram-Lindström, Nitya, Hammarberg, Anders, Beck, Olof, Franck, Johan · 2008 · American Journal of Psychiatry

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Currently there is no approved pharmacotherapy for amphetamine dependence. Recent human laboratory studies have demonstrated that naltrexone modulates some of the reinforcing effects of amphetamine. The aim of this study was to investigate the efficacy of naltrexone in comparison with placebo in reducing relapse to amphetamine use in amphetamine-dependent patients. METHOD: Eighty patients who met DSM-IV criteria for amphetamine dependence were randomized to 12 weeks of double-blind naltrexone (50 mg) or placebo treatment. Patients visited the clinic twice weekly to receive medication and relapse prevention therapy and leave urine samples, which were analyzed for drug toxicology and for assessing adherence to medication via detection of naltrexone's metabolite (6-beta-naltrexol). The main outcome measure was abstinence from amphetamine use, as indicated by the total number of negative amphetamine urine samples during 12 weeks of treatment. All missing urine samples were defined for the analysis as positive for amphetamine. RESULTS: Overall, 55 patients (68.8%) completed the trial. The intention-to-treat analysis showed that the naltrexone group had a significantly higher number of amphetamine-negative urine samples compared with the placebo group. Survival analyses showed that the treatment groups differed in rate of continuous abstinence, in both the intention-to-treat and completer samples, in favor of naltrexone treatment. There was a significant reduction in craving levels and self-reported consumption of amphetamine in the naltrexone group compared with the placebo group. Treatment with naltrexone was well tolerated in this sample. CONCLUSIONS: This trial demonstrated the efficacy of naltrexone in reducing amphetamine use in amphetamine-dependent individuals.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2008.08020304

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 26 references

Research works printed but not linked: 5

  1. United Nations Office on Drugs and Crime, 2005, Drug Report
  2. Swedish Council for Information on Alcohol and Other Drugs, 2006, Drug Trends in Sweden
  3. Srisurapanont M, 2001, Cochrane Database Syst Rev, 4, D003022
  4. Sobell LC, 1992, Measuring Alcohol Consumption, 44
  5. Lee MC, 1988, J Nucl Med, 29, 1207

Cited by

Items 101–185 of 185

Metadata

Authors
Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J.
Venue
American Journal of Psychiatry
Published
2008-11
Volume
165
Issue
11
Pages
1442-1448
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2116763568
Cited by
185
References
26
Citations by year
2025: 11 · 2024: 8 · 2023: 6 · 2022: 8 · 2021: 6 · 2020: 12 · 2019: 5 · 2018: 11 · 2017: 11 · 2016: 9 · 2015: 17 · 2014: 18 · 2013: 15 · 2012: 16
FWCI
7.42
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
naltrexone, amphetamine dependence, pharmacotherapy, relapse prevention, abstinence, craving, urine drug testing, medication adherence
MeSH terms
Adult, Amphetamine, Double-Blind Method, Female, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Substance Withdrawal Syndrome, Substance Abuse Detection, Survival Analysis, Treatment Outcome, Amphetamine-Related Disorders, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.